Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium

Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably, radionuclide drug conjugates (RDC), specifically 177Lu/11...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yuanhong, Wu, Siyu, Li, Rong, Yu, Jiazheng, Zheng, Jianyi, Li, Zeyu, Li, Mingyang, Xin, Kerong, Xu, Zhenqun, Li, Shijie, Chen, Xiaonan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391859/
https://www.ncbi.nlm.nih.gov/pubmed/37528464
http://dx.doi.org/10.1186/s40164-023-00430-1
_version_ 1785082814343938048
author Jiang, Yuanhong
Wu, Siyu
Li, Rong
Yu, Jiazheng
Zheng, Jianyi
Li, Zeyu
Li, Mingyang
Xin, Kerong
Xu, Zhenqun
Li, Shijie
Chen, Xiaonan
author_facet Jiang, Yuanhong
Wu, Siyu
Li, Rong
Yu, Jiazheng
Zheng, Jianyi
Li, Zeyu
Li, Mingyang
Xin, Kerong
Xu, Zhenqun
Li, Shijie
Chen, Xiaonan
author_sort Jiang, Yuanhong
collection PubMed
description Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably, radionuclide drug conjugates (RDC), specifically 177Lu/111In-J591 and 225Ac-J591, exhibited enhanced therapeutic efficacy in treating patients with CRPC. Furthermore, promising treatment approaches for CRPC included dual anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) blockade in rare tumors (DART)-Lorigerlimab, prostate stem cell antigen (PSCA)-directed chimeric antigen receptor (CAR)-T cell immunotherapy-BPX-601, and protein kinase inhibitor (AKTi)-CAPltello-280. We have summarized the latest CRPC treatment strategies presented at the 2023 ASCO-GU Cancers Symposium, along with recent advances in CRPC clinical trials.
format Online
Article
Text
id pubmed-10391859
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103918592023-08-02 Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium Jiang, Yuanhong Wu, Siyu Li, Rong Yu, Jiazheng Zheng, Jianyi Li, Zeyu Li, Mingyang Xin, Kerong Xu, Zhenqun Li, Shijie Chen, Xiaonan Exp Hematol Oncol Correspondence Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably, radionuclide drug conjugates (RDC), specifically 177Lu/111In-J591 and 225Ac-J591, exhibited enhanced therapeutic efficacy in treating patients with CRPC. Furthermore, promising treatment approaches for CRPC included dual anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) blockade in rare tumors (DART)-Lorigerlimab, prostate stem cell antigen (PSCA)-directed chimeric antigen receptor (CAR)-T cell immunotherapy-BPX-601, and protein kinase inhibitor (AKTi)-CAPltello-280. We have summarized the latest CRPC treatment strategies presented at the 2023 ASCO-GU Cancers Symposium, along with recent advances in CRPC clinical trials. BioMed Central 2023-08-01 /pmc/articles/PMC10391859/ /pubmed/37528464 http://dx.doi.org/10.1186/s40164-023-00430-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Jiang, Yuanhong
Wu, Siyu
Li, Rong
Yu, Jiazheng
Zheng, Jianyi
Li, Zeyu
Li, Mingyang
Xin, Kerong
Xu, Zhenqun
Li, Shijie
Chen, Xiaonan
Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium
title Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium
title_full Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium
title_fullStr Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium
title_full_unstemmed Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium
title_short Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium
title_sort novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 asco-gu cancers symposium
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391859/
https://www.ncbi.nlm.nih.gov/pubmed/37528464
http://dx.doi.org/10.1186/s40164-023-00430-1
work_keys_str_mv AT jiangyuanhong novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium
AT wusiyu novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium
AT lirong novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium
AT yujiazheng novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium
AT zhengjianyi novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium
AT lizeyu novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium
AT limingyang novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium
AT xinkerong novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium
AT xuzhenqun novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium
AT lishijie novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium
AT chenxiaonan novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium

Ejemplares similares